Neutralization of the Staphylococcus aureus Panton-Valentine leukocidin by African and Caucasian sera.
BMC Microbiol
; 22(1): 219, 2022 09 17.
Article
in En
| MEDLINE
| ID: mdl-36115948
ABSTRACT
BACKGROUND:
The prevalence of Staphylococcus aureus isolates carrying the Panton-Valentine leukocidin (PVL) gene is higher in Africa (≈50%) compared to Europe (< 5%). The study aimed to measure anti-PVL-antibodies in Africans and Germans in a multi-center study and to test whether detected antibodies can neutralize the cytotoxic effect of PVL on polymorphonuclear leukocytes (PMNs).METHODS:
Sera from asymptomatic Africans (n = 22, Nigeria, Gabon) and Caucasians (n = 22, Germany) were used to quantify antibody titers against PVL and α-hemolysin (in arbitrary units [AU]) by ELISA. PMNs from one African and German donor were exposed to 5 nM recombinant PVL to measure the neutralizing effect of serial dilutions of pooled sera from African and Caucasian participants, or donor sera at 0.625 and 2.5% (v/v).RESULTS:
Anti-PVL-antibodies were significantly higher in Africans than in Germans (1.9 vs. 0.7 AU, p < 0.0001). The pooled sera from the study participants neutralized the cytotoxic effect of PVL on African and German PMNs in a dose dependent manner. Also, neutralization of PVL on PMNs from the African and German donors had a stronger effect with African sera (half-maximal inhibitory concentration (IC50) = 0.27 and 0.47%, respectively) compared to Caucasian sera (IC50 = 3.51 and 3.59% respectively).CONCLUSION:
Africans have higher levels of neutralizing anti-PVL-antibodies. It remains unclear if or at what level these antibodies protect against PVL-related diseases.Key words
Full text:
1
Database:
MEDLINE
Main subject:
Staphylococcal Infections
/
Staphylococcus aureus
/
Antibodies, Neutralizing
/
Leukocidins
/
Neutrophils
Type of study:
Clinical_trials
/
Risk_factors_studies
Limits:
Humans
Country/Region as subject:
Africa
/
Europa
Language:
En
Year:
2022
Type:
Article